On August 18, 2025 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported agenda topics for its in-person R&D Day in conjunction with the company’s 10-Year Anniversary on September 8, 2025 in New York from 8:00-10:30am EST (Press release, Ideaya Biosciences, AUG 18, 2025, View Source [SID1234655361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of IDEAYA’s senior leadership team will provide an overview of the company’s progress to date, including presentation of new clinical data on darovasertib in neoadjuvant uveal melanoma (UM), IDE849 (DLL3 TOP1 ADC) and IDE397 (MAT2A), and outline key areas of focus as part of their future growth strategy. Details of the R&D Day agenda are below.

Agenda topics

IDEAYA 10-Year Anniversary and R&D Day Introduction
Darovasertib (PKC)
Phase 2 Neoadjuvant UM Data in Plaque Brachytherapy-eligible Patients
IDE849 (DLL3 TOP1 ADC)
Phase 1 SCLC Data from the 2025 World Conference on Lung Cancer (WCLC)
Mechanistic Data from 2025 WCLC to Support Combination of TOP1-ADCs with IDE161/PARG
IDE397 (MAT2A)
Combination Rationale with Trodelvy (TROP2 TOP1 ADC) in MTAP-deletion solid tumors
Initial Phase 1 Clinical Data from IDE397/Trodelvy Combination in MTAP-deletion urothelial cancer
IDE892 (PRMT5)
Potentially Best-in-Class PRMT5 Profile and Combination Opportunity with IDE397 (MAT2A) in MTAP-deletion solid tumors
Application of AI/ML in Our Discovery Capabilities
Closing Remarks and Q&A
Joining IDEAYA’s leadership team at the R&D Day will be Dr. Arun D. Singh, Director of the Department of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic. Dr. Singh will present data from IDEAYA’s Phase 2 trial of darovasertib in the neoadjuvant setting of UM and discuss the design and objectives of IDEAYA’s recently initiated Phase 3 OptimUM-10 trial to support a potential approval in this indication.

A live question and answer session will follow the presentation. Registration for this event can be accessed here or through the IDEAYA website View Source